Potential Roles of Myeloid Differentiation Factor 2 on Neuroinflammation and Its Possible Interventions
- PMID: 32803490
- DOI: 10.1007/s12035-020-02066-2
Potential Roles of Myeloid Differentiation Factor 2 on Neuroinflammation and Its Possible Interventions
Abstract
Neuroinflammation is the primary response by immune cells in the nervous system to protect against infection. Chronic and uncontrolled neuroinflammation triggers neuronal injury and neuronal death resulting in a variety of neurodegenerative disorders. Therefore, fine tuning of the immune response in the nervous system is now extensively considered as a potential therapeutic intervention for those diseases. The immune cells of the nervous system express Toll-like receptor 4 (TLR4) together with myeloid differentiation factor 2 (MD-2) to protect against the pathogens. Over the last 10 years, antagonists targeting the functional domains of MD-2 have become attractive pharmacological intervention strategies in pre-clinical studies into neuroinflammation and its associated brain pathologies. This review aims to summarize and discuss the roles of TLR4-MD-2 signaling pathway activation in various models of neuroinflammation. This review article also highlights the studies reporting the effect of MD-2 antagonists on neuroinflammation in in vitro and in vivo studies.
Keywords: Brain function; Lipopolysaccharide; Myeloid differentiation factor 2; Neuroinflammation; Toll-like receptor 4.
Similar articles
-
Structural insights into pharmacophore-assisted in silico identification of protein-protein interaction inhibitors for inhibition of human toll-like receptor 4 - myeloid differentiation factor-2 (hTLR4-MD-2) complex.J Biomol Struct Dyn. 2019 May;37(8):1968-1991. doi: 10.1080/07391102.2018.1474804. Epub 2018 May 29. J Biomol Struct Dyn. 2019. PMID: 29842849
-
Myeloid differentiation protein 2 silencing decreases LPS-induced cytokine production and TLR4/MyD88 pathway activity in alveolar macrophages.Immunol Lett. 2011 Dec 30;141(1):94-101. doi: 10.1016/j.imlet.2011.07.010. Epub 2011 Aug 9. Immunol Lett. 2011. PMID: 21849156
-
Inhibition of myeloid differentiation protein 2 attenuates renal ischemia/reperfusion-induced oxidative stress and inflammation via suppressing TLR4/TRAF6/NF-kB pathway.Life Sci. 2020 Sep 1;256:117864. doi: 10.1016/j.lfs.2020.117864. Epub 2020 May 29. Life Sci. 2020. PMID: 32474021
-
Myeloid differentiation 2 as a therapeutic target of inflammatory disorders.Pharmacol Ther. 2012 Mar;133(3):291-8. doi: 10.1016/j.pharmthera.2011.11.001. Epub 2011 Nov 19. Pharmacol Ther. 2012. PMID: 22119168 Review.
-
Ciprofloxacin and levofloxacin attenuate microglia inflammatory response via TLR4/NF-kB pathway.J Neuroinflammation. 2019 Jul 18;16(1):148. doi: 10.1186/s12974-019-1538-9. J Neuroinflammation. 2019. PMID: 31319868 Free PMC article. Review.
Cited by
-
Blocking Brain Myeloid Differentiation Factor 2-Toll-like Receptor 4 Signaling Improves Cognition by Diminishing Brain Pathologies and Preserving Adult Hippocampal Neurogenesis in Obese Rats.J Neuroimmune Pharmacol. 2024 Oct 7;19(1):51. doi: 10.1007/s11481-024-10151-9. J Neuroimmune Pharmacol. 2024. PMID: 39373789
-
Ischemic stroke and diabetes: a TLR4-mediated neuroinflammatory perspective.J Mol Med (Berl). 2024 Jun;102(6):709-717. doi: 10.1007/s00109-024-02441-9. Epub 2024 Mar 28. J Mol Med (Berl). 2024. PMID: 38538987 Review.
-
Myeloid differentiation factor 2 inhibitors exert protective effects on lipopolysaccharides-treated human dental pulp cells via suppression of toll-like receptor 4-mediated signaling.J Dent Sci. 2024 Jan;19(1):220-230. doi: 10.1016/j.jds.2023.04.024. Epub 2023 May 5. J Dent Sci. 2024. PMID: 38303896 Free PMC article.
-
An Updated Review of Mitochondrial Transplantation as a Potential Therapeutic Strategy Against Cerebral Ischemia and Cerebral Ischemia/Reperfusion Injury.Mol Neurobiol. 2023 Apr;60(4):1865-1883. doi: 10.1007/s12035-022-03200-y. Epub 2023 Jan 3. Mol Neurobiol. 2023. PMID: 36595193 Review.
-
Selective targeting of MD2 attenuates intestinal inflammation and prevents neonatal necrotizing enterocolitis by suppressing TLR4 signaling.Front Immunol. 2022 Nov 1;13:995791. doi: 10.3389/fimmu.2022.995791. eCollection 2022. Front Immunol. 2022. PMID: 36389716 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources